Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

NCT04795713 is registered in ClinicalTrials.gov with Molecular Templates, Inc. as lead sponsor.

NCT NCT04795713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04795713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Lead sponsor
Molecular Templates, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 27, 2021
Completion date
October 31, 2024
Enrollment
64 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, non-small cell lung cancer, squamous cell carcinoma of head and neck